title: Melanotropins as drugs for the treatment of obesity and other feeding disorders: potential and problems.
abstract: Current biological and pharmacological evidence suggests that the melanocortin 4 and melanocortin 3 receptors which are seven transmembrane G-protein coupled receptors (GPCRs) are involved in various aspects of energy balance and feeding behaviors in animals including humans. The natural endogenous ligands for these receptors are products of the gene pro-opiomelanocortin (POMC), and include alpha-melanocyte stimulating hormone, gamma-melanocyte stimulating hormone and perhaps other modified products of POMC. Thus well designed agonists and antagonists of these ligands might serve as drugs for the treatment of feeding disorders. However, these melanotropin peptides also can have other biological activities that involve the MC3R and MC4R, and these other biological properties will need to be modulated in ligands that are likely to be useful drugs for feeding disorders. Current progress in these areas with special emphasis on the MC3R will be discussed along with possible new directions that might be fruitful in these important aspects of contemporary biology and medicine.
authors.affiliation: Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA.
authors.forename: Minying
authors.initials: M
authors.lastname: Cai
authors.forename: Joel
authors.initials: J
authors.lastname: Nyberg
authors.forename: Victor J
authors.initials: VJ
authors.lastname: Hruby
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009074:Melanocyte-Stimulating Hormones / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D009748:Nutrition Disorders / Q000188:drug therapy* / Q000378:metabolism; D044104:Receptor, Melanocortin, Type 3 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000502:physiology; D044105:Receptor, Melanocortin, Type 4 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology; D013329:Structure-Activity Relationship
chemical_list: D019440:Anti-Obesity Agents; D044104:Receptor, Melanocortin, Type 3; D044105:Receptor, Melanocortin, Type 4; D009074:Melanocyte-Stimulating Hormones
references.citation: Nat Genet. 2000 Sep;26(1):97-102
references.pmid: 10973258
references.citation: Am J Physiol Regul Integr Comp Physiol. 2004 Mar;286(3):R417-30
references.pmid: 14761863
references.citation: Neuroimmunomodulation. 1996 Sep-Oct;3(5):259-84
references.pmid: 9218248
references.citation: Hypertension. 1987 Dec;10(6):619-27
references.pmid: 3692573
references.citation: J Pharmacol Exp Ther. 2008 Jun;325(3):927-34
references.pmid: 18322151
references.citation: J Med Chem. 2003 Aug 14;46(17):3728-33
references.pmid: 12904077
references.citation: Diabetes. 2007 Oct;56(10):2622-30
references.pmid: 17639020
references.citation: J Immunol. 2003 Mar 15;170(6):3323-30
references.pmid: 12626592
references.citation: J Neurosci. 1999 Sep 15;19(18):RC26
references.pmid: 10479719
references.citation: Am J Physiol. 1998 Apr;274(4):R931-8
references.pmid: 9575953
references.citation: J Med Chem. 2002 Jun 6;45(12):2644-50
references.pmid: 12036373
references.citation: Curr Top Med Chem. 2007;7(11):1098-1106
references.pmid: 17584130
references.citation: Curr Top Med Chem. 2007;7(11):1107-19
references.pmid: 17584128
references.citation: Biochem Pharmacol. 2007 Aug 1;74(3):383-91
references.pmid: 17572390
references.citation: J Med Chem. 1987 Nov;30(11):2126-30
references.pmid: 2822931
references.citation: Endocrinology. 2000 Sep;141(9):3518-21
references.pmid: 10965927
references.citation: Peptides. 2006 Feb;27(2):259-64
references.pmid: 16274853
references.citation: J Leukoc Biol. 2001 Jan;69(1):98-104
references.pmid: 11200074
references.citation: J Med Chem. 2000 Dec 28;43(26):4998-5002
references.pmid: 11150170
references.citation: J Med Chem. 2005 Mar 24;48(6):1839-48
references.pmid: 15771429
references.citation: Bioorg Med Chem Lett. 2006 Oct 15;16(20):5462-7
references.pmid: 16931008
references.citation: Endocrinology. 1972 Mar;90(3):700-6
references.pmid: 5009346
references.citation: Urology. 2000 Oct 1;56(4):641-6
references.pmid: 11018622
references.citation: J Neurosci. 1996 Aug 15;16(16):5182-8
references.pmid: 8756446
references.citation: J Med Chem. 1995 Sep 1;38(18):3454-61
references.pmid: 7658432
references.citation: Neuroscience. 1992;48(2):463-8
references.pmid: 1318515
references.citation: J Med Chem. 2008 Jan 24;51(2):187-95
references.pmid: 18088090
references.citation: Trends Pharmacol Sci. 2007 Dec;28(12):615-20
references.pmid: 18022255
references.citation: Nature. 1997 Jan 9;385(6612):165-8
references.pmid: 8990120
references.citation: Curr Top Med Chem. 2007;7(11):1121-30
references.pmid: 17584132
references.citation: J Clin Endocrinol Metab. 2004 Aug;89(8):3936-42
references.pmid: 15292330
references.citation: Arthritis Rheum. 2002 Oct;46(10):2765-75
references.pmid: 12384937
references.citation: J Pharmacol Exp Ther. 2005 Jan;312(1):382-90
references.pmid: 15333678
references.citation: ACS Chem Biol. 2008 Sep 19;3(9):530-41
references.pmid: 18652471
references.citation: Peptides. 2005 Aug;26(8):1481-5
references.pmid: 15876475
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4867-72
references.pmid: 12663858
references.citation: Recept Channels. 2002;8(5-6):261-8
references.pmid: 12690954
references.citation: J Med Chem. 2009 Jun 25;52(12):3627-35
references.pmid: 19473029
references.citation: J Neurosci. 2008 Nov 26;28(48):12946-55
references.pmid: 19036988
references.citation: Curr Neuropharmacol. 2007 Sep;5(3):149-56
references.pmid: 19305797
references.citation: Nat Rev Drug Discov. 2009 Jan;8(1):41-54
references.pmid: 19116626
references.citation: Ann N Y Acad Sci. 2003 Jun;994:12-20
references.pmid: 12851293
references.citation: Am J Physiol. 1997 Jun;272(6 Pt 2):R1946-53
references.pmid: 9227612
references.citation: J Med Chem. 2006 Mar 23;49(6):1946-52
references.pmid: 16539382
references.citation: Am J Physiol. 1986 Jul;251(1 Pt 1):E134-7
references.pmid: 3014888
references.citation: Eur J Pharmacol. 1995 Dec 29;294(2-3):795-803
references.pmid: 8750747
references.citation: J Pept Res. 2004 Feb;63(2):116-31
references.pmid: 15009533
references.citation: Endocr Rev. 2006 Dec;27(7):736-49
references.pmid: 17077189
references.citation: Peptides. 2008 Mar;29(3):440-7
references.pmid: 18155809
references.citation: Gen Comp Endocrinol. 1989 Jan;73(1):157-63
references.pmid: 2537778
references.citation: Biochem Pharmacol. 2008 Aug 15;76(4):520-30
references.pmid: 18614155
references.citation: Endocrinology. 2006 May;147(5):2183-96
references.pmid: 16469808
references.citation: J Leukoc Biol. 2004 Oct;76(4):845-53
references.pmid: 15277567
references.citation: J Biol Chem. 2007 Jul 27;282(30):21712-9
references.pmid: 17545153
references.citation: Drug Discov Today. 2004 Sep 1;9(17):752-8
references.pmid: 15450241
references.citation: Obes Rev. 2003 Nov;4(4):239-48
references.pmid: 14649374
references.citation: Biochemistry. 2006 Jan 31;45(4):1128-37
references.pmid: 16430209
references.citation: Eur J Pharmacol. 2002 Nov 1;454(1):71-9
references.pmid: 12409007
references.citation: Eur J Pharmacol. 2001 Oct 19;429(1-3):61-9
references.pmid: 11698027
references.citation: Br J Pharmacol. 1997 Apr;120(8):1561-7
references.pmid: 9113379
references.citation: J Hypertens. 2006 Nov;24(11):2239-46
references.pmid: 17053546
references.citation: Curr Opin Pharmacol. 2003 Oct;3(5):551-6
references.pmid: 14559102
references.citation: J Urol. 1998 Aug;160(2):389-93
references.pmid: 9679884
references.citation: Nat Rev Drug Discov. 2002 Mar;1(3):198-210
references.pmid: 12120504
references.citation: Curr Opin Chem Biol. 2008 Jun;12(3):269-80
references.pmid: 18342020
references.citation: Nature. 2001 May 24;411(6836):480-4
references.pmid: 11373681
references.citation: Curr Pharm Des. 2004;10(17):2003-13
references.pmid: 15279541
references.citation: Pharmacol Rev. 2002 Jun;54(2):323-74
references.pmid: 12037145
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):177-82
references.pmid: 12122505
references.citation: Bioorg Med Chem Lett. 2007 May 1;17(9):2492-8
references.pmid: 17314042